Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2− Early Breast Cancer 2025
Treatment Algorithm for HR+ / HER2- EBC
Axillary Management for HR+ / HER2− EBC
Adjuvant Treatment of HR+ / HER2- EBC with ET +/- CDK4/6 inhibitor
Access the Kisqali Clinical Input CDA PDF
Access the Kisqali Clinical Input INESSS PDF
